Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report.

Furuse M, Nonoguchi N, Omura N, Shirahata M, Iwasaki K, Inui T, Kuroiwa T, Kuwabara H, Miyatake SI.

Neurol Med Chir (Tokyo). 2017 Apr 15;57(4):191-197. doi: 10.2176/nmc.cr.2016-0330. Epub 2017 Mar 23.

2.

Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis.

Chamberlain MC, Kormanik P, Glantz M.

Oncol Rep. 1998 Mar-Apr;5(2):521-5.

PMID:
9468593
3.

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.

Zhao D, Qian L, Shen J, Liu X, Mei K, Cen J, Wang Y, Li C, Ma Y.

J Cell Mol Med. 2014 Jun;18(6):1081-6. doi: 10.1111/jcmm.12252. Epub 2014 Mar 13.

4.

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA.

Blood. 2017 Jun 8;129(23):3071-3073. doi: 10.1182/blood-2017-01-764209. Epub 2017 Mar 29.

5.

Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.

Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F.

J Neurooncol. 2007 Jul;83(3):291-3. Epub 2007 Jan 24.

PMID:
17245621
6.

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

Enting RH, Demopoulos A, DeAngelis LM, Abrey LE.

Neurology. 2004 Sep 14;63(5):901-3. Review.

PMID:
15365145
7.

Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.

Cheah CY, Milgrom S, Chihara D, Gombos DS, Pinnix CC, Dabaja BS, Fowler NH.

Neuro Oncol. 2016 Apr;18(4):575-81. doi: 10.1093/neuonc/nov253. Epub 2015 Oct 20.

8.

Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.

Murakami M, Fujimaki T, Asano S, Nakaguchi H, Yamada SM, Hoya K, Yamazaki K, Ishida Y, Matsuno A.

Yonsei Med J. 2011 Nov;52(6):1031-4. doi: 10.3349/ymj.2011.52.6.1031.

9.

Late relapse in primary central nervous system lymphoma: clonal persistence.

Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM.

Neuro Oncol. 2011 May;13(5):525-9. doi: 10.1093/neuonc/nor014. Epub 2011 Mar 3.

10.

Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.

Zheng J, Wang C, Liu F.

World Neurosurg. 2018 Sep;117:316-320. doi: 10.1016/j.wneu.2018.06.150. Epub 2018 Jun 27.

PMID:
29960094
11.

Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation.

Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H.

Bone Marrow Transplant. 1996 Nov;18(5):1021-3.

PMID:
8932861
12.

Biology and treatment of primary central nervous system lymphoma.

Algazi AP, Kadoch C, Rubenstein JL.

Neurotherapeutics. 2009 Jul;6(3):587-97. doi: 10.1016/j.nurt.2009.04.013. Review.

13.

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.

Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V.

J Clin Oncol. 2001 Feb 1;19(3):742-9.

PMID:
11157026
14.

[Therapeutic management of central nervous system lymphomas in a single hematological institute].

Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C.

Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703. Hungarian.

PMID:
19812012
15.

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F.

Eur J Haematol. 2003 Apr;70(4):219-24.

PMID:
12656744
16.

Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma.

Fujii Y, Nishikawa Y, Nomura M, Miyamoto S, Uneno Y, Horimatsu T, Muto M.

Intern Med. 2018 Apr 15;57(8):1173-1176. doi: 10.2169/internalmedicine.8910-17. Epub 2017 Dec 21.

17.

Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

Chamberlain MC.

J Neurooncol. 2014 May;118(1):155-62. doi: 10.1007/s11060-014-1411-8. Epub 2014 Mar 1.

PMID:
24584709
18.

Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy.

DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G.

Neurology. 1990 Jan;40(1):80-6.

PMID:
2296388
19.

Incidence and radiographic findings of primary central nervous system lymphoma in immunocompetent patients in southern Thailand.

Rujirojindakul P, Rohitoprakarn M, Kongkabpan D, Viboonjantra P, Lekhakula A.

Tumori. 2008 May-Jun;94(3):304-8.

PMID:
18705395
20.

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

J Clin Oncol. 2008 May 20;26(15):2512-8. doi: 10.1200/JCO.2007.13.5533. Epub 2008 Apr 14.

PMID:
18413641

Supplemental Content

Support Center